Monjuvi U.S. net product sales of US$ 20.8 million (€ 19.4 million) for the first quarter of 2023 Enrollment of Phase 3 MANIFEST-2 study of pelabresib in first-line myelofibrosis is complete, with topline
03.05.2023 - EQS-News: MorphoSys AG / Key word(s): Quarterly / Interim Statement MorphoSys AG Reports First Quarter 2023 Financial Results 03.05.2023 / 22:01 CET/CEST The issuer is solely responsible for the content of this announcement. Media Release .
Topline data from the Phase 3 MANIFEST-2 study expected in early 2024 Monjuvi U.S. net product sales of US$ 25.3 million (€ 24.7 million) for the fourth quarter of 2022 and US$ 89.4 million (€ 84.9